EUVIMEDEUVIMED entdecken
Crossref

A combined model of serum neutrophil extracellular traps, CD 8 + T cells, and tumor proportion score provides better prediction of PD ‐1 inhibitor efficacy in patients with NSCLC

Jian Guo, Tingting Shu, Hao Zhang, Nan Huang, Junxi Ren, Li Lin, Jianhua Wu, Yuanyuan Wang, Zhenhua Huang, Jianping Bin, Yulin Liao, Min Shi und 2 weitere

The FEBS Journal · 2024

DOI: 10.1111/febs.17144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FEBS Journal, 2024. Verfasst von Jian Guo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Extracellular Traps, CD8-Positive T-Lymphocytes, Lung Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Natural Science Foundation of Guangdong Province, Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors provide a definite survival benefit for patients with driver‐negative advanced non‐small cell lung cancer (NSCLC), but predictors of efficacy are still lacking. There may be a relationship between immune inflammatory state and tumor immune response. We explored the relationship of serum neutrophil extracellular traps (NETs) with infiltrating cells in the tumor tissues of patients with NSCLC as well as their relationship with the therapeutic efficacy of programmed cell death protein 1 (PD‐1) inhibitors. Serum myeloperoxidase (MPO)‐double‐stranded DNA (dsDNA) was detected as a marker of NET serum concentration. T cells were detected by immunohistochemical staining, and neutrophils were counted by MPO immunofluorescence staining. Of the 31 patients with NSCLC, a longer progression‐free survival after PD‐1 inhibitor treatment was associated with higher levels of CD3 + T cells, a lower neutrophil : CD3 + ‐T‐cell ratio (NEU/CD3 + ) and lower neutrophil : CD8 + ‐T‐cell ratio (NEU/CD8 + ) in tumor tissues. Patients with higher serum NETs were more likely to develop progressive disease after treatment ( P = 0.003) and to have immune‐related adverse events (IrAEs) as well as higher NEU/CD3 + and NEU/CD8 + . The combined model of serum NETs, CD8 + T cells, and tumor proportion score (TPS) significantly improved the prediction of PD‐1 inhibitor efficacy [ P = 0.033; area under the curve (AUC) = 0.881]. Our results indicate that serum NETs are effective predictors of PD‐1 inhibitor response and reflect the tissue neutrophil‐to‐lymphocyte ratio and IrAE levels. The combined model of serum NETs, CD8 + T cells, and TPS is a powerful tool for predicting the efficacy of PD‐1 inhibitor treatment in patients with NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungExtracellular TrapsCD8-Positive T-LymphocytesLung NeoplasmsImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorHumansFemaleMaleMiddle AgedAgedNeutrophilsAdult

Stichwörter der Autor:innen

CD8+ T cellsPD‐1 inhibitorsneutrophil extracellular trapneutrophil‐to‐lymphocyte rationon‐small cell lung cancer

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China.

ORCID-Profile: Wangjun Liao, Na Huang

Förderung

  • Natural Science Foundation of Guangdong Province
  • Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University
  • National Natural Science Foundation of China

Zitieren

APA

Guo, J., Shu, T., Zhang, H., Huang, N., Ren, J., Lin, L., Wu, J., Wang, Y., Huang, Z., Bin, J., Liao, Y., Shi, M., Liao, W., & Huang, N. (2024). A combined model of serum neutrophil extracellular traps, CD 8 + T cells, and tumor proportion score provides better prediction of PD ‐1 inhibitor efficacy in patients with NSCLC. The FEBS Journal. https://doi.org/10.1111/febs.17144

Vancouver

Guo J, Shu T, Zhang H, Huang N, Ren J, Lin L, et al. A combined model of serum neutrophil extracellular traps, CD 8 + T cells, and tumor proportion score provides better prediction of PD ‐1 inhibitor efficacy in patients with NSCLC. The FEBS Journal. 2024. doi:10.1111/febs.17144

BibTeX
@article{Guo2024,
  author = {Guo, Jian and Shu, Tingting and Zhang, Hao and Huang, Nan and Ren, Junxi and Lin, Li and Wu, Jianhua and Wang, Yuanyuan and Huang, Zhenhua and Bin, Jianping and Liao, Yulin and Shi, Min and Liao, Wangjun and Huang, Na},
  title = {A combined model of serum neutrophil extracellular traps, CD 8 + T cells, and tumor proportion score provides better prediction of PD ‐1 inhibitor efficacy in patients with NSCLC},
  journal = {The FEBS Journal},
  year = {2024},
  doi = {10.1111/febs.17144}
}
Kostenlos starten →